Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People's Republic of China and Southeast Asia. Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein-Barr virus (EBV) infection. The presen...
Saved in:
Published in | Therapeutics and clinical risk management Vol. 10; no. default; pp. 721 - 736 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.01.2014
Taylor & Francis Ltd Dove Press Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People's Republic of China and Southeast Asia. Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein-Barr virus (EBV) infection. The presence of EBV in all tumor cells, aberrant pattern of antibodies against EBV antigens in patient sera, and elevated viral DNA in patient circulation as well as nasopharyngeal site underline the role of EBV during NPC development. In NPC tumors, EBV expresses latency type II, where three EBV-encoded proteins, Epstein-Barr nuclear antigen 1, latent membrane protein 1 and 2 (LMP1, 2), are expressed along with BamH1-A rightward reading frame 1, Epstein-Barr virus-encoded small nuclear RNAs, and BamH1-A rightward transcripts. Among all encoded proteins, LMP1 plays a central role in the propagation of NPC. Standard treatment of NPC consists of radiotherapy with or without chemotherapy for early stage, concurrent chemoradiotherapy in locally advanced tumors, and palliative systemic chemotherapy in metastatic disease. However, this standard care has limitations, allowing recurrences and disease progression in a certain proportion of cases. Although the pathophysiological link and molecular process of EBV-induced oncogenesis are not fully understood, therapeutic approaches targeting the virus may increase the cure rate and add clinical benefit. The promising results of early phase clinical trials on EBV-specific immunotherapy, epigenetic therapy, and treatment with viral lytic induction offer new options for treating NPC. |
---|---|
AbstractList | Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People's Republic of China and Southeast Asia. Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein–Barr virus (EBV) infection. The presence of EBV in all tumor cells, aberrant pattern of antibodies against EBV antigens in patient sera, and elevated viral DNA in patient circulation as well as nasopharyngeal site underline the role of EBV during NPC development. In NPC tumors, EBV expresses latency type II, where three EBV-encoded proteins, Epstein–Barr nuclear antigen 1, latent membrane protein 1 and 2 (LMP1, 2), are expressed along with BamH1-A rightward reading frame 1, Epstein–Barr virus-encoded small nuclear RNAs, and BamH1-A rightward transcripts. Among all encoded proteins, LMP1 plays a central role in the propagation of NPC. Standard treatment of NPC consists of radiotherapy with or without chemotherapy for early stage, concurrent chemoradiotherapy in locally advanced tumors, and palliative systemic chemotherapy in metastatic disease. However, this standard care has limitations, allowing recurrences and disease progression in a certain proportion of cases. Although the pathophysiological link and molecular process of EBV-induced oncogenesis are not fully understood, therapeutic approaches targeting the virus may increase the cure rate and add clinical benefit. The promising results of early phase clinical trials on EBV-specific immunotherapy, epigenetic therapy, and treatment with viral lytic induction offer new options for treating NPC. Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People's Republic of China and Southeast Asia. Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein-Barr virus (EBV) infection. The presence of EBV in all tumor cells, aberrant pattern of antibodies against EBV antigens in patient sera, and elevated viral DNA in patient circulation as well as nasopharyngeal site underline the role of EBV during NPC development. In NPC tumors, EBV expresses latency type II, where three EBV-encoded proteins, Epstein-Barr nuclear antigen 1, latent membrane protein 1 and 2 (LMP1, 2), are expressed along with BamH1-A rightward reading frame 1, Epstein-Barr virus-encoded small nuclear RNAs, and BamH1-A rightward transcripts. Among all encoded proteins, LMP1 plays a central role in the propagation of NPC. Standard treatment of NPC consists of radiotherapy with or without chemotherapy for early stage, concurrent chemoradiotherapy in locally advanced tumors, and palliative systemic chemotherapy in metastatic disease. However, this standard care has limitations, allowing recurrences and disease progression in a certain proportion of cases. Although the pathophysiological link and molecular process of EBV-induced oncogenesis are not fully understood, therapeutic approaches targeting the virus may increase the cure rate and add clinical benefit. The promising results of early phase clinical trials on EBV-specific immunotherapy, epigenetic therapy, and treatment with viral lytic induction offer new options for treating NPC. Keywords: immunotherapy, epigenetic therapy, viral lytic induction therapy Susanna Hilda Hutajulu,1 Johan Kurnianda,1I Bing Tan,2,3 Jaap M Middeldorp4 1Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia; 2Department of Ear, Nose and Throat, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; 3Department of Ear, Nose and Throat, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia; 4Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands Abstract: Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People's Republic of China and Southeast Asia. Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein-Barr virus (EBV) infection. The presence of EBV in all tumor cells, aberrant pattern of antibodies against EBV antigens in patient sera, and elevated viral DNA in patient circulation as well as nasopharyngeal site underline the role of EBV during NPC development. In NPC tumors, EBV expresses latency type II, where three EBV-encoded proteins, Epstein-Barr nuclear antigen 1, latent membrane protein 1 and 2 (LMP1, 2), are expressed along with BamH1-A rightward reading frame 1, Epstein-Barr virus-encoded small nuclear RNAs, and BamH1-A rightward transcripts. Among all encoded proteins, LMP1 plays a central role in the propagation of NPC. Standard treatment of NPC consists of radiotherapy with or without chemotherapy for early stage, concurrent chemoradiotherapy in locally advanced tumors, and palliative systemic chemotherapy in metastatic disease. However, this standard care has limitations, allowing recurrences and disease progression in a certain proportion of cases. Although the pathophysiological link and molecular process of EBV-induced oncogenesis are not fully understood, therapeutic approaches targeting the virus may increase the cure rate and add clinical benefit. The promising results of early phase clinical trials on EBV-specific immunotherapy, epigenetic therapy, and treatment with viral lytic induction offer new options for treating NPC. Keywords: immunotherapy, epigenetic therapy, viral lytic induction therapy |
Audience | Academic |
Author | Tan, I Bing Hutajulu, Susanna Hilda Middeldorp, Jaap M Kurnianda, Johan |
AuthorAffiliation | 2 Department of Ear, Nose and Throat, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands 1 Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia 3 Department of Ear, Nose and Throat, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia 4 Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands |
AuthorAffiliation_xml | – name: 1 Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia – name: 4 Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands – name: 3 Department of Ear, Nose and Throat, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia – name: 2 Department of Ear, Nose and Throat, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands |
Author_xml | – sequence: 1 givenname: Susanna Hilda surname: Hutajulu fullname: Hutajulu, Susanna Hilda organization: Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia – sequence: 2 givenname: Johan surname: Kurnianda fullname: Kurnianda, Johan organization: Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia – sequence: 3 givenname: I Bing surname: Tan fullname: Tan, I Bing organization: Department of Ear, Nose and Throat, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands ; Department of Ear, Nose and Throat, Faculty of Medicine Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia – sequence: 4 givenname: Jaap M surname: Middeldorp fullname: Middeldorp, Jaap M organization: Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25228810$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkt9rFDEQxxep2B_65LssCCLI1vzabPZFqEfVQkXQCr6F2dzkLsfuZpvsFvzvzd61tVd8kDwkTD7zzUzme5wd9L7HLHtJySmjonp_tfj-9fSHqAQXT7IjSitVMMJ_HWzPspCcy8PsOMYNIULWNX2WHbKSMaUoOcrs1RoDDDiNzuSuG1pnYHS-j7m3-fkQR3R98RFCyG9cmGLueotmBnLrQz6uMR8DwthhP84ZPUQ_rCH87lcIbW4gGNf7Dp5nTy20EV_c7ifZz0_nV4svxeW3zxeLs8vCSErGgiowSEBVFfLlEkrLVFXWUBIjSFNXvMKGLxsEY4DWDTBhmK04Q2WUqhkiP8kudrpLDxs9BNelWrQHp7cBH1YaQmq1Rd1waZGhFZSjMFaALI2qOQMKVjZQJq0PO61hajpcmtRigHZPdP-md2u98jdaUElLTpIAuSvmBoeAMT6q6C5qfKepYkymlLe3bwZ_PWEcdeeiwbaFHv0UNS2lVKJU8r9QTiSt2FzI60foxk-hT4PQjLG6SqYQ4i-1gvQ9adA-dWVmUX0mqGAVo2p-9vQfVFpL7JxJzrQuxfcS3jxIWCdbjOvo22nrsn3w3Q40wccY0N7_FiV6drqena53Tk_0q4fTuWfvrM3_AKT2_Bc |
CitedBy_id | crossref_primary_10_1016_j_virusres_2017_04_019 crossref_primary_10_3892_mmr_2017_6694 crossref_primary_10_1016_j_oraloncology_2016_07_010 crossref_primary_10_1111_coa_12834 crossref_primary_10_1016_j_apjtm_2015_07_007 crossref_primary_10_3892_ol_2018_9216 crossref_primary_10_3892_mco_2016_1041 crossref_primary_10_1371_journal_ppat_1006404 crossref_primary_10_1177_0885328217692964 crossref_primary_10_3390_cancers10040086 crossref_primary_10_3390_jcm6120111 crossref_primary_10_3390_cancers10040089 crossref_primary_10_1016_j_peptides_2016_09_008 crossref_primary_10_1097_MS9_0000000000000963 crossref_primary_10_1016_j_bbrc_2016_05_146 crossref_primary_10_1016_j_rpor_2015_05_007 crossref_primary_10_1371_journal_pone_0202537 crossref_primary_10_1007_s13277_015_4464_1 crossref_primary_10_3390_cancers12082142 crossref_primary_10_1186_s12885_016_2517_5 crossref_primary_10_1093_nar_gkw875 crossref_primary_10_1038_s41698_017_0018_x crossref_primary_10_1002_jmv_24870 crossref_primary_10_1089_omi_2021_0052 crossref_primary_10_3390_biomedicines11051344 crossref_primary_10_3390_cancers12071940 crossref_primary_10_1016_j_canlet_2016_05_032 crossref_primary_10_1007_s00432_015_1969_3 crossref_primary_10_1200_JCO_2015_60_7846 crossref_primary_10_1038_s41598_019_39732_y |
ContentType | Journal Article |
Copyright | COPYRIGHT 2014 Dove Medical Press Limited 2014. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2014 Hutajulu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2014 |
Copyright_xml | – notice: COPYRIGHT 2014 Dove Medical Press Limited – notice: 2014. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2014 Hutajulu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2014 |
DBID | NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88C 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M2O MBDVC NAPCQ PIMPY PQEST PQQKQ PQUKI Q9U 7X8 7U1 7U2 7U9 C1K H94 5PM DOA |
DOI | 10.2147/TCRM.S47434 |
DatabaseName | PubMed CrossRef ProQuest Central (Corporate) ProQuest Nursing & Allied Health Database ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) ProQuest Healthcare Administration Database ProQuest Research Library Research Library (Corporate) Nursing & Allied Health Premium Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic Risk Abstracts Safety Science and Risk Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic Risk Abstracts AIDS and Cancer Research Abstracts Virology and AIDS Abstracts Safety Science and Risk Environmental Sciences and Pollution Management |
DatabaseTitleList | Publicly Available Content Database Risk Abstracts PubMed |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1178-203X |
EndPage | 736 |
ExternalDocumentID | oai_doaj_org_article_b36fe2ef413e4cf4a65c8932a1af6ba5 oai_dovepress_com_18226 A414272186 10_2147_TCRM_S47434 25228810 |
Genre | Journal Article Review |
GeographicLocations | Netherlands China Indonesia Southeast Asia China, People's Rep |
GeographicLocations_xml | – name: Netherlands – name: China – name: Indonesia – name: Southeast Asia – name: China, People's Rep |
GroupedDBID | --- 0YH 123 29Q 2WC 53G 5VS 6PF 7RV 7X7 8AO 8FI 8FJ 8G5 AAWTL ABDBF ABUWG ACGFO ADBBV ADRAZ AENEX AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AQUVI AZQEC BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI CCPQU CS3 DIK DWQXO E3Z EBD EBS EJD ESX F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR IHW ITC KQ8 M0T M2O M48 M~E NAPCQ NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RNS RPM TR2 TUS UKHRP VDV AAYXX CITATION TDBHL 3V. 7XB 8FK K9. MBDVC PQEST PQUKI Q9U 7X8 7U1 7U2 7U9 C1K H94 - ABPTK ADACO BBAFP LI0 5PM |
ID | FETCH-LOGICAL-c610t-18ace0a877e3dda5f28759a50c40b9737eb3dbeacca19ba24c2f732e8c8892ee3 |
IEDL.DBID | RPM |
ISSN | 1176-6336 1178-203X |
IngestDate | Fri Oct 04 13:04:20 EDT 2024 Tue Sep 17 21:11:45 EDT 2024 Mon Jan 18 10:57:33 EST 2021 Fri Aug 16 21:28:04 EDT 2024 Fri Aug 16 22:20:06 EDT 2024 Tue Sep 24 19:59:53 EDT 2024 Fri Feb 23 00:16:56 EST 2024 Fri Feb 02 04:22:57 EST 2024 Tue Aug 20 22:10:03 EDT 2024 Thu Sep 26 15:46:46 EDT 2024 Sat Sep 28 08:15:38 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | default |
Keywords | immunotherapy viral lytic induction therapy epigenetic therapy |
Language | English |
License | The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c610t-18ace0a877e3dda5f28759a50c40b9737eb3dbeacca19ba24c2f732e8c8892ee3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161530/ |
PMID | 25228810 |
PQID | 2229799144 |
PQPubID | 3933272 |
PageCount | 16 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_b36fe2ef413e4cf4a65c8932a1af6ba5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4161530 dovepress_primary_oai_dovepress_com_18226 proquest_miscellaneous_1566845866 proquest_miscellaneous_1563061720 proquest_journals_2229799144 gale_infotracmisc_A414272186 gale_infotracacademiconefile_A414272186 gale_healthsolutions_A414272186 crossref_primary_10_2147_TCRM_S47434 pubmed_primary_25228810 |
PublicationCentury | 2000 |
PublicationDate | 2014-01-01 |
PublicationDateYYYYMMDD | 2014-01-01 |
PublicationDate_xml | – month: 01 year: 2014 text: 2014-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand – name: Macclesfield |
PublicationTitle | Therapeutics and clinical risk management |
PublicationTitleAlternate | Ther Clin Risk Manag |
PublicationYear | 2014 |
Publisher | Dove Medical Press Limited Taylor & Francis Ltd Dove Press Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Taylor & Francis Ltd – name: Dove Press – name: Dove Medical Press |
References | 19584275 - Cancer Res. 2009 Jul 15;69(14):5734-42 22687948 - Semin Radiat Oncol. 2012 Jul;22(3):233-44 23683686 - Curr Opin Virol. 2013 Jun;3(3):227-32 20967865 - Head Neck. 2011 Jul;33(7):969-75 11668481 - Int J Cancer. 2001 Oct 1;94(1):73-80 9833758 - Int J Cancer. 1998 Dec 9;78(6):675-9 14747554 - J Virol. 2004 Feb;78(4):1893-902 19853674 - Biochim Biophys Acta. 2010 Mar-Apr;1799(3-4):228-35 20124988 - Anticancer Drugs. 2010 Jun;21(5):471-7 20719947 - J Virol. 2010 Nov;84(21):11113-23 23403548 - Drug Des Devel Ther. 2013;7:37-52 9356498 - Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12616-21 21177151 - Eur Ann Otorhinolaryngol Head Neck Dis. 2011 Apr;128(2):79-85 15613356 - J Virol. 2005 Jan;79(2):1296-307 11408227 - Antimicrob Agents Chemother. 2001 Jul;45(7):2082-91 12118254 - Nat Genet. 2002 Aug;31(4):395-9 14585276 - Clin Immunol. 2003 Oct;109(1):53-63 20727127 - BMC Cancer. 2010 Aug 20;10 :446 10599304 - Virchows Arch. 1999 Aug;435(2):79-86 10989829 - Oncology (Williston Park). 2000 Aug;14(8):1223-30; discussion 1232-7, 1239-42 12468425 - Blood. 2003 Apr 15;101(8):3150-6 7540805 - Am J Otolaryngol. 1995 Mar-Apr;16(2):103-8 21272441 - Chin J Cancer. 2011 Feb;30(2):96-105 19846527 - J Virol. 2010 Jan;84(1):407-17 24457012 - Semin Cancer Biol. 2014 Jun;26:60-8 15093894 - Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):11-20 8705861 - Nat Med. 1996 Aug;2(8):906-11 9768759 - Immunity. 1998 Sep;9(3):395-404 19471857 - Invest New Drugs. 2010 Aug;28(4):413-20 22313344 - Expert Opin Ther Targets. 2012 Mar;16 Suppl 1:S63-8 15324698 - Cancer Cell. 2004 Aug;6(2):151-8 20304794 - Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6328-33 14694109 - J Virol. 2004 Jan;78(2):768-78 15510157 - Nat Rev Cancer. 2004 Oct;4(10):757-68 20017928 - Head Neck Oncol. 2009 Dec 17;1:40 22169768 - Mol Cancer Ther. 2012 Mar;11(3):594-603 19091858 - J Virol. 2009 Mar;83(5):2357-67 1968116 - Lancet. 1990 Feb 17;335(8686):371-4 9338076 - Adv Cancer Res. 1998;72:141-96 22761471 - Clin Cancer Res. 2012 Sep 15;18(18):5061-70 21821548 - Ann Oncol. 2012 Apr;23(4):997-1005 16264907 - Nat Clin Pract Oncol. 2005 Mar;2(3):138-49 24155638 - Curr Oncol. 2013 Oct;20(5):e406-19 17911266 - Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9 17704426 - J Clin Oncol. 2007 Aug 20;25(24):3766-73 18539384 - Cancer Lett. 2008 Oct 18;270(1):66-76 20605352 - Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):148-53 18213730 - Head Neck. 2008 Jul;30(7):863-7 19296536 - Int J Cancer. 2009 Jun 15;124(12):2942-7 15778977 - J Med Virol. 2005 May;76(1):82-8 16720343 - Front Biosci. 2006 Sep 01;11:2672-713 24297049 - Mol Ther. 2014 Jan;22(1):132-9 8985194 - J Infect Dis. 1997 Jan;175(1):38-46 19196381 - Int J Lab Hematol. 2010 Feb;32(1 Pt 1):e169-74 2732001 - Int J Cancer. 1989 Jun 15;43(6):1077-82 18331451 - Traffic. 2008 Jun;9(6):871-81 3022942 - Cell. 1986 Dec 26;47(6):883-9 17762933 - Cancer Chemother Pharmacol. 2008 Jun;62(1):59-64 20944593 - Nat Biotechnol. 2010 Oct;28(10):1033-8 21439244 - Chin J Cancer. 2011 Apr;30(4):231-9 7778675 - Am J Pathol. 1995 Jun;146(6):1355-67 9520415 - Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3621-6 17557295 - Int J Cancer. 2007 Oct 15;121(8):1806-12 17156439 - BMC Cancer. 2006 Dec 08;6:283 12226824 - J Med Virol. 2002 Nov;68(3):370-7 9565632 - J Exp Med. 1998 May 4;187(9):1395-402 2425959 - Cancer Res. 1986 Sep;46(9):4831-6 8453591 - Cancer. 1993 Apr 15;71(8):2689-97 19079156 - Mucosal Immunol. 2008 Jan;1(1):11-22 8985380 - J Virol. 1997 Jan;71(1):519-26 15006927 - Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):482-6 11034107 - Cancer Res. 2000 Oct 1;60(19):5584-8 14769850 - J Exp Med. 2004 Feb 16;199(4):459-70 18977445 - Semin Cancer Biol. 2008 Dec;18(6):397-408 16951192 - Cancer Res. 2006 Sep 1;66(17):8762-9 23170171 - Viruses. 2012 Sep;4(9):1537-47 16597877 - J Clin Microbiol. 2006 Apr;44(4):1459-67 16204009 - J Clin Oncol. 2005 Dec 10;23(35):8942-9 21123379 - J Virol. 2011 Feb;85(4):1604-14 12434416 - J Pathol. 2002 Dec;198(4):468-75 17987110 - PLoS One. 2007 Nov 07;2(11):e1122 7829236 - Int J Cancer. 1995 Jan 27;60(3):315-20 17477889 - Expert Rev Mol Med. 2007 May 04;9(12):1-24 24351754 - Clin Vaccine Immunol. 2014 Feb;21(2):256-9 23024765 - PLoS One. 2012;7(9):e44810 8970991 - J Virol. 1996 Dec;70(12 ):8653-9 15507648 - J Virol. 2004 Nov;78(22):12613-24 21330921 - Curr Opin Oncol. 2011 May;23(3):254-8 22104426 - Am J Med Sci. 2012 Jun;343(6):483-9 11801549 - Clin Cancer Res. 2002 Jan;8(1):131-7 19013244 - Semin Cancer Biol. 2008 Dec;18(6):388-96 8386141 - Int J Cancer. 1993 Apr 1;53(6):957-62 7714494 - J Med Virol. 1995 Jan;45(1):71-7 20869957 - Chem Biol Interact. 2010 Dec 5;188(3):623-34 11093820 - Int J Cancer. 2000 Dec 15;88(6):949-55 17315195 - Int J Cancer. 2007 Jun 1;120(11):2401-10 21544243 - PLoS One. 2011 Apr 22;6(4):e19100 18726711 - Fam Cancer. 2009;8(2):103-8 15026332 - Cancer Res. 2004 Mar 15;64(6):1972-4 20737217 - Ann Surg Oncol. 2011 Jan;18(1):233-8 11959880 - Jpn J Clin Oncol. 2002 Mar;32 Suppl:S66-81 18073197 - Nucleic Acids Res. 2008 Feb;36(2):666-75 9971778 - J Virol. 1999 Mar;73(3):1980-9 6254061 - Proc Natl Acad Sci U S A. 1980 Sep;77(9):5163-6 17378764 - Annu Rev Immunol. 2007;25:587-617 15546396 - Immunol Rev. 2004 Dec;202:223-36 1515979 - Cancer. 1992 Sep 1;70(5):1024-9 11912175 - Cancer Res. 2002 Mar 15;62(6):1920-6 14688409 - Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 7769701 - J Virol. 1995 Jul;69(7):4390-8 16572427 - Int J Cancer. 2006 Aug 1;119(3):608-14 2155423 - Proc Natl Acad Sci U S A. 1990 Mar;87(5):1725-9 15540234 - Cancer. 2005 Jan 1;103(1):211; author reply 211-2 23996634 - Rev Med Virol. 2013 Nov;23(6):367-83 16804839 - Clin Infect Dis. 2006 Aug 1;43(3):276-82 21586688 - Ann Oncol. 2012 Feb;23(2):435-41 24157866 - Cell Death Dis. 2013 Oct 24;4:e872 1511442 - Cancer Res. 1992 Sep 1;52(17):4787-90 8903467 - Int J Cancer. 1996 Nov 4;68(3):285-90 19005181 - Blood. 2009 Feb 26;113(9):1957-66 12740922 - Int J Cancer. 2003 Jul 10;105(5):706-9 23785114 - Am J Epidemiol. 2013 Aug 1;178(3):325-38 19234486 - Oncogene. 2009 Apr 9;28(14):1725-35 21336546 - Int J Hematol. 2011 Mar;93(3):281-93 23689138 - Cancer Lett. 2013 Aug 28;337(1):1-7 23118544 - Onco Targets Ther. 2012;5:297-308 22431025 - J Med Virol. 2012 May;84(5):768-76 15148340 - J Exp Med. 2004 May 17;199(10):1421-31 19578433 - PLoS Pathog. 2009 Jul;5(7):e1000496 21640213 - Biochim Biophys Acta. 2011 Nov-Dec;1809(11-12):631-40 16229803 - Neoplasia. 2005 Sep;7(9):809-15 9552031 - J Clin Oncol. 1998 Apr;16(4):1310-7 15809453 - J Clin Oncol. 2005 May 20;23(15):3568-76 10438853 - J Virol. 1999 Sep;73(9):7627-32 8174667 - Epidemiol Rev. 1993;15(2):466-85 18838543 - J Exp Med. 2008 Oct 27;205(11):2551-60 10197635 - Cancer Res. 1999 Apr 1;59(7):1599-605 17360652 - Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3366-71 11992124 - Nat Genet. 2002 Jun;31(2):141-9 18991568 - Curr Cancer Drug Targets. 2008 Nov;8(7):591-6 10861098 - J Immunol. 2000 Jul 1;165(1):573-82 19327912 - Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):734-41 12450728 - Semin Cancer Biol. 2002 Dec;12(6):421-9 21123521 - Clin Vaccine Immunol. 2011 Feb;18(2):298-304 10216473 - Anticancer Res. 1999 Jan-Feb;19(1B):661-5 21317222 - Ann Oncol. 2011 Jun;22(6):1280-7 8437863 - Oncogene. 1993 Mar;8(3):791-5 19442504 - Curr Opin Cell Biol. 2009 Aug;21(4):575-81 20421267 - Haematologica. 2010 Oct;95(10):1769-77 22880099 - PLoS One. 2012;7(8):e42767 1847471 - J Virol. 1991 Mar;65(3):1558-67 18197201 - Eur J Hum Genet. 2008 Mar;16(3):343-9 2983224 - Nature. 1985 Feb 28-Mar 6;313(6005):812-5 22261816 - Int J Cancer. 2012 Oct 15;131(8):1930-40 23777485 - BMC Cancer. 2013 Jun 18;13:293 23342374 - Viruses. 2012 Dec;4(12):3701-30 15803189 - Mod Pathol. 2005 Jul;18(7):877-85 15542583 - Blood. 2005 Mar 1;105(5):1898-904 19884659 - J Clin Invest. 2009 Dec;119(12 ):3626-36 9628848 - Blood Cells Mol Dis. 1998 Jun;24(2):114-23 15842731 - Virol J. 2005 Apr 20;2:39 7637746 - N Engl J Med. 1995 Sep 14;333(11):693-8 11129022 - Laryngoscope. 2000 Dec;110(12):2066-9 21535891 - Mol Cancer. 2011 May 02;10:48 23502768 - J Immunother. 2013 Apr;36(3):208-14 22249143 - Semin Cancer Biol. 2012 Apr;22(2):144-53 19726497 - J Virol. 2009 Nov;83(22):11734-45 20426903 - Chin J Cancer. 2010 May;29(5):517-26 17178861 - Cancer Res. 2006 Dec 15;66(24):11668-76 22106024 - Head Neck. 2013 Jan;35(1):133-45 22300735 - Semin Cancer Biol. 2012 Apr;22(2):107-16 8541116 - Eur J Cancer. 1995 Oct;31A(11):1875-8 17951399 - Mol Cancer Res. 2007 Oct;5(10):981-9 24206918 - Chin J Cancer. 2013 Nov;32(11):604-13 22178394 - Semin Cancer Biol. 2012 Apr;22(2):166-72 19557156 - PLoS Pathog. 2009 Jun;5(6):e1000490 12810882 - J Gen Virol. 2003 Jul;84(Pt 7):1871-9 15195243 - J Infect Dis. 2004 Jul 1;190(1):53-62 2449354 - Eur J Cancer Clin Oncol. 1987 Dec;23(12):1921-4 16170180 - J Clin Oncol. 2005 Sep 20;23(27):6730-8 15611975 - Cancer. 2005 Feb 1;103(3):569-75 19429479 - Semin Cancer Biol. 2009 Jun;19(3):158-64 22178121 - Lancet Oncol. 2012 Feb;13(2):172-80 22659417 - Biochem Biophys Res Commun. 2012 Jun 29;423(2):313-8 9875407 - Antivir Chem Chemother. 1998 May;9(3):275-82 10802367 - Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):405-12 15007085 - J Clin Oncol. 2004 Apr 15;22(8):1373-81 17285127 - Br J Cancer. 2007 Feb 26;96(4):623-30 23006945 - Cancer J. 2012 Sep-Oct;18(5):411-20 6172387 - Int J Cancer. 1981 Aug 15;28(2):131-5 18039120 - Annu Rev Pathol. 2006;1:375-404 23031715 - Curr Opin Virol. 2012 Dec;2(6):733-9 2846609 - J Virol Methods. 1988 Sep;21(1-4):133-46 19889783 - J Virol. 2010 Jan;84(2):1158-68 2394508 - Int J Cancer. 1990 Sep 15;46(3):421-5 15752890 - Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1107-16 23348421 - Cancer Res. 2013 Mar 15;73(6):1676-88 12460912 - Cancer Res. 2002 Dec 1;62(23):6952-8 21527913 - EMBO J. 2011 Jun 1;30(11):2115-29 10878338 - J Immunol. 2000 Jul 15;165(2):663-70 19386431 - Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1481-6 20080768 - Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):872-7 22210180 - Semin Cancer Biol. 2012 Apr;22(2):162-5 19874382 - Clin Microbiol Infect. 2009 Nov;15(11):982-8 23255783 - Am J Epidemiol. 2013 Feb 1;177(3):242-50 18528464 - Trans Am Clin Climatol Assoc. 2006;117: |
References_xml | |
SSID | ssj0046991 |
Score | 2.2274542 |
SecondaryResourceType | review_article |
Snippet | Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People's Republic of China and Southeast Asia. Its etiology is unique and... Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People’s Republic of China and Southeast Asia. Its etiology is unique and... Susanna Hilda Hutajulu,1 Johan Kurnianda,1I Bing Tan,2,3 Jaap M Middeldorp4 1Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada/Dr... |
SourceID | doaj pubmedcentral dovepress proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 721 |
SubjectTerms | Antigens Cancer therapies Care and treatment Chemotherapy epigenetic therapy Epstein-Barr virus Gene expression Genomes Health aspects immunotherapy Infections Kinases Lymphocytes Lymphoma Nasopharyngeal cancer Pathogenesis Review Throat cancer Tumors viral lytic induction therapy |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQL8AB8U2ggJGqIqSGxokTO8e2alUhFVWwlfZm2Y5T9kBSJbuV9t8zEydpAhJcuMZ2InvGM292Z94QsgdqI8GPFmGcGhPy3InQpIkIU5NpYXKtTVfHffE1O7_iX5bpctLqC3PCPD2wP7hDk2Sli10JxtZxW3KdpRZ8bKyZLjOjPXspS4dgyttgiPm6XnmMCdSDZOkr87Anz-Hi5NvF5-8cPCef-aKOsv8huV_Utz4H9U8jPfFS8wzKiUs6e0we9ViSHvk9PCH3XPWU7F96MurtAV3c1Va1B3SfXt7RVG-fkXIyTFeTxHJal_T0psU2mOGxbhp6u2o2LR3StioKOJcCbqRjkjquqDQ2RNDNtroG7Ekt9iiq6p_6Obk6O12cnId914XQApRah0xq6yIthXBJUei0hJgqzXUaWR6ZXCQCwu_CgL22muVGx9zGpUhiJ62Ueexc8oLsVHXlXhEalUxLAFyRyfD_wgi5CW3CkgJWCmuigOwN569uPLmGgqAExaRQTMqLKSDHKJtxCjJidw9AT1SvJ-pfehKQT6Nkf3vT8BSuuIJwK84C8h4lr3wp6mgD1BFnPBbYxSsgH7sZaAVAAazuixlg38inNZu5O5sJt9fOhwftUr31aBX2WBegwRy2_mEcxpWYEVe5etMqhsRuCD-jv87JJE9lBp956RV23HoMwFtKBqvFTJVnZzMfqVY_Ov5x3kUJ0ev_IZY35AFAUO5_1NolO-tm494CzFubd92N_gWBslPc priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELfGeAAeEP8JDDDSNIS00DhxYucJbdOmCmlogk7qm2U7ztYHkpK2k_rGd-Ab8km4y782IO01ttumd777nX13P0L2QW0k-NHMD2NjfJ464Zs4En5sEi1MqrWp67jPvybjS_5lGk93yLirhcG0ys4m1oY6Ky2ekY-Qd1oAmOF8pA2eAtjl6PP8p4_8UXjP2pJp3CF3WQiwAjRbTPvQC2LAmjuPMZH4SYQXlliphxw9o8nJt_NP3zl4Uj7wTXUL_wfkXlbeNDmp_xvtLa81zKjcclFnj8jDFlvSo0YZHpMdVzwhBxdNc-r1IZ1saq0Wh_SAXmzaVq-fkuutYTrbSjSnZU5P5wukxfzz6_exrip6M6tWC9olchUUkC8FJEn7tHVcU2ikSNDVurgCNEotshYV5Q_9jFyenU5Oxn7Lw-BbAFdLn0ltXaClEC7KMh3nEGXFqY4DywOTikhAQJ4ZsOBWs9TokNswF1HopJUyDZ2LnpPdoizcS0KDnGkJECwwCd4gBtit0EYsymClsCbwyH4nATVv2m0oCFNQUAoFpRpBeeQYpdNPwR7Z9YOyulLtllMmSnIXuhzctOM25zqJLaCzUDOdJ0bHHvnYy_afT-qeggIqCMDCxCPvUPaqKU7trYI64oyHAnm9PPKhnoF2AbVTt-UN8N7YYWswc28wE_azHQ53-qVae7JQG-33yPt-GFdijlzhytVCMWz1hoA0uHVOInksE_iaF43K9q8eAhSXksFqMVDmwX8zHClm13VHcl7HDcGr23_6a3If4CZvDrD2yO6yWrk3AOmW5m29W_8CjE9PoQ priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9RAEF9qfVAfxM8arbpCqQhNTTab7OZBpC0tRTgpegd9W3Y3m3qgSU3uivffO5OvXqoIPh1kZ-7YnZmd31zmg5AdUBsJfjTzWWyMz1MnfBNHwo9NooVJtTZNHffkc3I645_O4_MN0g_j7A6w_mtoh_OkZtX3_V8_Vx_B4D9gGnPIxfvp0ZfJ_lcOvpDfIrcZfKCqT_jwOgFCwDRsi_NuMozcUdO1_x65k5VXbRrqn_f0mqMaJ1GueaWTB-R-ByfpQSv_h2TDFY_I7lnbj3q1R6fX5VX1Ht2lZ9edqlePSb62TOdrueW0zOnxZY2TMP1DXVX0al4ta9pnbhUUoC4F6EiHPHXkKDTORNDVqrgA-Ektjikqyh_6CZmdHE-PTv1u8IJvAU0t_FBq6wIthXBRluk4h7AqTnUcWB6YVEQCIvDMwJVtdZgazbhluYiYk1bKlDkXPSWbRVm4Z4QGeaglYK7AJPjKMMD2hDYKoww4hTWBR3b681eXbX8NBXEJikmhmFQrJo8comwGEmyK3TwoqwvV2ZgyUZI75nLwy47bnOsktgDHmA51nhgde-TdINkb39Q_BStXEHGxxCOvUfKqrUYdrgF1wEPOBA7y8sjbhgJVExTA6q6eAfaNLbVGlNsjSjBgO17utUv1-q9wzLoAreWw9TfDMnJiUlzhymWtQuzthgg0-CdNInksE_iZrVZhh60zwN5ShsAtRqo8OpvxSjH_1rQg502gEDz_jxN9Qe4C2OTt31fbZHNRLd1LAHQL86ox1t_JlFC2 priority: 102 providerName: Scholars Portal |
Title | Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25228810 https://www.proquest.com/docview/2229799144/abstract/ https://search.proquest.com/docview/1563061720 https://search.proquest.com/docview/1566845866 http://www.dovepress.com/getfile.php?fileID=21483 https://pubmed.ncbi.nlm.nih.gov/PMC4161530 https://doaj.org/article/b36fe2ef413e4cf4a65c8932a1af6ba5 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF615QAcEM9iKGGRqiKkOvFj7V0fmyhVhZQqKqnUm7W7XreRiB05SaXc-A_8Q34JM341BokDlxy8s4k38_rGngchxyA2AvxoYnuBUjaLDLdV4HM7UKHkKpJSlXXck8vw4pp9vQlu9kjQ1MKUSftazfvZ90U_m9-VuZXLhR40eWKD6WTESpjiDPbJPvf9JkSvzC-Ee-WYPNfloR36-G4Si_JwHM9gNrqa9L8xcJo4jscD6CEEls7ueKSycf9T8jjJ76tM1L9N9Y6v6uZR7jim8-fkWY0o6Vl15y_InslekpNp1ZJ6e0pnDxVWq1N6QqcPzaq3r8jdzjKd76SX0zyl4-UKh2H--vFzKIuC3s-LzYo26VsZBbxLAT_SNlkd92QSByPIYpvdAgalGmcVZflCvibX5-PZ6MKupy_YGiDV2naF1MaRgnPjJ4kMUoitgkgGjmaOirjPIQxPFNhtLd1ISY9pL-W-Z4QWIvKM8d-QgyzPzFtCndSVAoCXo0J8b-hgj0Ltu34CO7lWjkWOGw7Ey6rJRgzBCfIsRp7FFc8sMkTutCTYGbu8kBe3cS0fsfLD1HgmBedsmE6ZDAMNmMyTrkxDJQOLfGl5-8c3NVdB1WMIu7zQIh-R93FVktragviMuczjOM3LIp9LCrQGIAJa1kUNcG7sq9WhPOpQghbr7nIjX3FtRVYxzlrnIM4Mjv6pXcadmBmXmXyzil1s8IYw1PknTShYIEL4mcNKZNujN1pgEd4R5s5_010BtSz7kNdq-O6_d74nTwB_suqJ1hE5WBcb8wEw3lr1QLNveI88Go4vp1e98kkJfE6Y6JXa_ht5kVkG |
link.rule.ids | 230,315,733,786,790,870,891,2115,2236,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829,74102,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELdgPAweEP8JDGakaQhpYUnsxMkT2qZNBdZpgk7qm2U7ztaHJV3STuob34FvyCfhLknTBqS9xnbb9M53v7Pv7kfIDqhNDH40dYNQa5cnVrg6ZMINdaSETpTSdR338CwaXPBv43DcHrhVbVrl0ibWhjotDJ6R7yPvtAAww_mX6Y2LrFF4u9pSaNwnDzhjHFP6xLgLuCDyqxnzfF9EbsTwmhLr85CZZ3909GP4-ScH_8l7Hqlu3P-IbKbFbZOJ-r-pXvNV_TzKNcd08oQ8bhElPWhU4Cm5Z_NnZPe8aUm92KOjVYVVtUd36fmqWfXiOblaG6aTtfRyWmT0eFohGeafX78PVVnS20k5r-gyfSungHcp4EfaJavjmlwhMYIqF_klYFBqkKsoL67VC3Jxcjw6Grgt-4JrAFLNXD9WxnoqFsKyNFVhBrFVmKjQM9zTiWACwvBUg902yk-0CrgJMsECG5s4TgJr2UuykRe5fU2ol_kqBuDl6QjvDT3sUWiYz1JYKYz2HLKzlICcNk02JAQnKCiJgpKNoBxyiNLppmBn7PpBUV7KdqNJzaLMBjYD52y5ybiKQgOYLFC-yiKtQod86mT7zyctn4LaSQi7gsgh2yh72ZSkdrZAHnCfBwLZvBzysZ6B1gBUwKi2qAHeG_tq9WZu9WbCLjb94aV-ydaKVHKl8w750A3jSsyMy20xr6SPDd4Qhnp3zoliHsYRfM2rRmW7Vw8AgMexD6tFT5l7_01_JJ9c1X3IeR0teG_u_unbZHMwGp7K069n39-ShwA4eXOEtUU2ZuXcvgNQN9Pv6537F_AJTtQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9NAFB5BK7EcEDuGQgepKkKqiZexxz6hpjQqS6OopFJvo5nxuM0BO9hJpdz4D_xDfgnveUsMUq-eN7Gdt33P8xZC9kBsIvCjie0FStksNtxWgc_tQIWSq1hKVdVxn47Dk3P25SK4aPKfyiatsrWJlaFOco3fyAc4d5oDmGFskDZpEZNPo4_znzZOkMKT1macxm2yzVkYgIRvD4_Hk7PWLkMcWM3Pc10e2qGPh5ZYrYdzegbTo7PTD98ZeFPW809VG__75G6SX9d5qf8b7g3P1c-q3HBTo4fkQYMv6WEtEI_ILZM9JvuTukH16oBO1_VW5QHdp5N16-rVE3K1sUxnG8nmNE_p8bzE0Zh_fv0eyqKg17NiWdI2mSujgH4poEnapa7jnkzimARZrLJLQKRU4-SiLP8hn5Lz0fH06MRuZjHYGgDWwnYjqY0jI86NnyQySCHSCmIZOJo5KuY-h6A8UWDFtXRjJT2mvZT7nol0FMWeMf4zspXlmXlBqJO6MgIY5qgQTxEd7FiofddPYCfXyrHIXssBMa9bbggIVZBRAhklakZZZIjc6UiwT3Z1IS8uRaN2QvlhajyTgqs2TKdMhoEGhOZJV6ahkoFF3ne8_eeX2qsghAKCMC-0yC7yXtQFqp1lEIfMZR7H2V4WeVdRoG0AEdCyKXGA98YuWz3KnR4l6LTuL7fyJRqbUoq1BljkbbeMOzFPLjP5shQutntDUOrcSBNGLIhCuM3zWmS7V_cAjkeRC7t5T5h7_01_JZtdVV3JWRU7OC9vfvRdcgfUVnz7PP76itwD9Mnq71k7ZGtRLM1rQHgL9aZR3b9OmVR3 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+implications+of+Epstein-Barr+virus+infection+for+the+treatment+of+nasopharyngeal+carcinoma&rft.jtitle=Therapeutics+and+clinical+risk+management&rft.au=Hutajulu+SH&rft.au=Kurnianda+J&rft.au=Tan+IB&rft.au=Middeldorp+JM&rft.date=2014-01-01&rft.pub=Dove+Press&rft.eissn=1178-203X&rft_id=info:doi/10.2147%2FTCRM.S47434&rft.externalDBID=TCRM&rft.externalDocID=oai_dovepress_com_18226 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1176-6336&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1176-6336&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1176-6336&client=summon |